A Phase 3 interventional study of Carfilzomib and Bortezomib in Multiple Myeloma, sponsored by Amgen. Completed at 213 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-26.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.
Among the 113 studies testing carfilzomib in Multiple Myeloma, this one has the largest enrollment, is one of 14 that started in 2013, is one of 15 in phase 3, and was the 33rd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Natalie Callander · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Australia, Brazil and 5 more countries
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
By country, each count listing its studies:
carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 78 · Phase 3 15 · Phase 4 2
First in 2005; this study’s year is marked. 14 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 955 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 54 across the 113 interventional studies. Of the 67 that completed or were terminated, 46 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 113 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
43 studies in Multiple Myeloma by Amgen: none open now, none under way, none of them phase 3. Of 41 finished, 36 (88%) have results posted.
Among the 43 studies in Multiple Myeloma by Amgen, this one is the 3rd largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2013, is one of 11 in phase 3, and was the 21st registered.
Amgen’s Multiple Myeloma studies by the year they started, since 2005.
18 of the studies testing carfilzomib in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT04096066Phase 3Fondazione EMN Italy OnlusA Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | 2027-09-01 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04973605BeOne MedicinesA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | 2026-11 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 113 studies testing carfilzomib in Multiple Myeloma, from their registry updates:
Among Amgen’s 43 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade® (bortezomib), melphalan and prednisone (VMP).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
, as defined by 1 or more of the following (assessed within 21 days prior to randomization):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received carfilzomib administered in combination with melphalan and prednisone for nine 42-day cycles. Carfilzomib was administered as an intravenous (IV) infusion on days 1, 2, 8, 9, 22, 23, 29, and 30 of each 42-day cycle. The carfilzomib dose was at 20 mg/m² on cycle 1, days 1 and 2 followed by 36 mg/m² thereafter. On days 1 to 4, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².
Drug: Carfilzomib · Drug: Melphalan · Drug: Prednisone
Participants received bortezomib in combination with melphalan and prednisone for nine 42-day cycles. Bortezomib was administered either IV or subcutaneously at 1.3 mg/m² during cycles 1 to 4 on days 1, 4, 8, 11, 22, 25, 29, and 32 followed by 1.3 mg/m² during cycles 5 to 9 on days 1, 8, 22, and 29. On days 1 to 4 of each cycle, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².
Drug: Bortezomib · Drug: Melphalan · Drug: Prednisone
Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.
Also known as: Krypolis®
Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.
Also known as: Velcade®
Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.
Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.
Progression-Free Survival (PFS)
Progression-free survival was defined as the time from randomization to the earlier of documented disease progression or death due to any cause. PFS was analyzed using Kaplan-Meier methods. The duration of PFS was censored for participants with no baseline and/or post-baseline disease assessments, who started a new anti-cancer therapy before documentation of disease progression or death, death or disease progression after missed disease assessment of 100 consecutive days or longer, or who were alive without documentation of disease progression before the data cutoff date, including lost to follow-up prior to disease progression. Participants were evaluated for disease response and progression according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC), determined centrally using a validated computer algorithm in a blinded manner.
Time frame: From randomization until the data cut-off date of 15 July 2016; median follow-up time for PFS was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.
Overall Survival (OS)
Overall survival (OS) was defined as the time from randomization to the date of death (whatever the cause). Participants who were alive or lost to follow-up as of the data analysis cut-off date were censored on the date the patient was last known to be alive. Median overall survival was estimated using the Kaplan-Meier method.
Time frame: From randomization until the data cut-off date of 15 July 2016; median follow-up time for OS was 22.2 and 22.5 months in the bortezomib and carfilzomib arms respectively.
Overall Response Rate
Disease response was evaluated according to the IMWG-URC using a validated computer algorithm. Overall response was defined as the percentage of participants with a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM biopsy; VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-protein with urine M-protein \<100 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. PR: ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline.
Time frame: Disease response was assessed every 3 weeks during the first 54 weeks and every 6 weeks thereafter until PD or the data cut-off date of 15 July 2016; median follow-up time was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.
Complete Response Rate
Complete response rate was defined as the percentage of participants in each treatment group who achieved a sCR or CR per the IMWG-URC as their best response. sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM biopsy.
Time frame: Disease response was assessed every 3 weeks during the first 54 weeks and every 6 weeks thereafter until PD or the data cut-off date of 15 July 2016; median follow-up time was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.
Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy
Neuropathy events were defined as Grade 2 or higher peripheral neuropathy as specified by peripheral neuropathy Standardised Medical Dictionary for Regulatory Activities (MedDRA) Query, narrow (scope) (SMQN) terms. Peripheral neuropathy was assessed by neurologic exam and graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03: Grade 1: Asymptomatic; Grade 2: Moderate symptoms, limiting instrumental activities of daily living (ADL) Grade 3: Severe symptoms; limiting self-care ADL; Grade 4: Life-threatening consequences, urgent intervention indicated; Grade 5: Death.
Time frame: From the first dose of any study drug up to 30 days after the last dose of any study drug as of the data cut-off date of 15 July 2016; median duration of treatment was 52 weeks in both treatment groups.
European Organisation for Research and Treatment of Cancer Quality of Life Core Module (EORTC QLQ-C30) Global Health Status/Quality of Life (QOL) Scores
The EORTC QLQ-C30 is a validated self-rating questionnaire including 30 items used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale was scored between 0 and 100, with higher scores indicating better Global Health Status/QOL.
Time frame: Baseline, weeks 6, 12, 18, 24, 30, 36, 42 and 48
Number of Participants With Adverse Events
Adverse events (AEs)were graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03, where GRADE 1 = Mild; GRADE 2 = Moderate; GRADE 3 = Severe; GRADE 4 = Life-threatening; GRADE 5 = Fatal. A serious adverse event is an adverse event that met 1 or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * Congenital anomaly/birth defect * Important medical event that jeopardized the participant and may have required medical or surgical intervention to prevent 1 of the outcomes listed above. Treatment-related adverse events are adverse events considered related to at least 1 investigational product by the investigator, including those with unknown relationship.
Time frame: From the first dose of any study drug up to 30 days after the last dose of any study drug as of the data cut-off date of 15 July 2016; median duration of treatment was 52 weeks in both treatment groups.
This study was conducted at 183 centers in Argentina, Australia, Austria, Belgium, Bulgaria, Canada, China, Czech Republic, France, Germany, Greece, Hungary, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Poland, Romania, Russia, Singapore, South Korea, Spain, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, and United States.
| Milestone | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone |
|---|---|---|
| Started | 477 | 478 |
| Received treatment | 470 | 474 |
| Completed | 290 | 280 |
| Not completed | 187 | 198 |
| Withdrew: Adverse event | 64 | 74 |
| Withdrew: Death | 14 | 18 |
| Withdrew: Non-compliance | 16 | 20 |
| Withdrew: Withdrawal by subject | 15 | 14 |
| Withdrew: Physician decision | 9 | 8 |
| Withdrew: Disease progression | 54 | 48 |
| Withdrew: Other | 7 | 8 |
| Withdrew: Continuing treatment | 1 | 4 |
| Withdrew: Randomized but not dosed | 7 | 4 |
Progression-free survival was defined as the time from randomization to the earlier of documented disease progression or death due to any cause. PFS was analyzed using Kaplan-Meier methods. The duration of PFS was censored for participants with no baseline and/or post-baseline disease assessments, who started a new anti-cancer therapy before documentation of disease progression or death, death or disease progression after missed disease assessment of 100 consecutive days or longer, or who were alive without documentation of disease progression before the data cutoff date, including lost to follow-up prior to disease progression. Participants were evaluated for disease response and progression according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC), determined centrally using a validated computer algorithm in a blinded manner.
| months | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone |
|---|---|---|
| Progression-Free Survival (PFS) | 22.1 (20.8 to 24.4) | 22.3 (20.9 to 26.7) |
Overall survival (OS) was defined as the time from randomization to the date of death (whatever the cause). Participants who were alive or lost to follow-up as of the data analysis cut-off date were censored on the date the patient was last known to be alive. Median overall survival was estimated using the Kaplan-Meier method.
| months | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (31.5 to NA) |
Disease response was evaluated according to the IMWG-URC using a validated computer algorithm. Overall response was defined as the percentage of participants with a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM biopsy; VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-protein with urine M-protein \<100 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline. PR: ≥ 50% reduction of serum M-protein and reduction in urine M-protein by ≥ 90% or to \< 200 mg/24 hours. A ≥ 50% reduction in the size of soft tissue plasmacytomas if present at baseline.
| percentage of participants | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone |
|---|---|---|
| Overall Response Rate | 78.8 (74.9 to 82.4) | 84.3 (80.7 to 87.5) |
Complete response rate was defined as the percentage of participants in each treatment group who achieved a sCR or CR per the IMWG-URC as their best response. sCR: As for CR, normal serum free light chain (SFLC) ratio and no clonal cells in bone marrow (BM). CR: No immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in BM biopsy.
| percentage of participants | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone |
|---|---|---|
| Complete Response Rate | 23.1 (19.4 to 27.1) | 25.9 (22.1 to 30.1) |
Neuropathy events were defined as Grade 2 or higher peripheral neuropathy as specified by peripheral neuropathy Standardised Medical Dictionary for Regulatory Activities (MedDRA) Query, narrow (scope) (SMQN) terms. Peripheral neuropathy was assessed by neurologic exam and graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03: Grade 1: Asymptomatic; Grade 2: Moderate symptoms, limiting instrumental activities of daily living (ADL) Grade 3: Severe symptoms; limiting self-care ADL; Grade 4: Life-threatening consequences, urgent intervention indicated; Grade 5: Death.
| percentage of participants | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone |
|---|---|---|
| Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy | 35.1 (30.8 to 39.6) | 2.5 (1.3 to 4.4) |
The EORTC QLQ-C30 is a validated self-rating questionnaire including 30 items used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale was scored between 0 and 100, with higher scores indicating better Global Health Status/QOL.
| units on a scale | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone |
|---|---|---|
| Baseline (n = 425, 425) | 53.3 ± 21.9 | 53.9 ± 22.5 |
| Week 6 (n = 412, 407) | 56.2 ± 19.5 | 61.1 ± 19.6 |
| Week 12 (n = 376, 389) | 55.3 ± 19.8 | 62.4 ± 17.7 |
| Week 18 (n = 341, 369) | 55.7 ± 18.8 | 63.2 ± 17.4 |
| Week 24 (n = 320, 345) | 57.3 ± 17.6 | 63.3 ± 17.1 |
| Week 30 (n = 298, 317) | 61.6 ± 17.8 | 63.0 ± 17.8 |
| Week 36 (n = 285, 308) | 61.9 ± 17.5 | 64.0 ± 18.1 |
| Week 42 (n = 275, 288) | 63.3 ± 17.7 | 65.0 ± 18.1 |
| Week 48 (n = 261, 265) | 62.9 ± 18.4 | 65.1 ± 17.1 |
Adverse events (AEs)were graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03, where GRADE 1 = Mild; GRADE 2 = Moderate; GRADE 3 = Severe; GRADE 4 = Life-threatening; GRADE 5 = Fatal. A serious adverse event is an adverse event that met 1 or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * Congenital anomaly/birth defect * Important medical event that jeopardized the participant and may have required medical or surgical intervention to prevent 1 of the outcomes listed above. Treatment-related adverse events are adverse events considered related to at least 1 investigational product by the investigator, including those with unknown relationship.
| participants | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone |
|---|---|---|
| All adverse events | 454 | 460 |
| AEs ≥ grade 3 | 358 | 354 |
| Serious adverse events | 198 | 235 |
| Leading to discontinuation of study drug | 73 | 83 |
| Fatal adverse events | 20 | 31 |
| Treatment-related adverse events (TRAEs) | 431 | 408 |
| TRAEs ≥ grade 3 | 285 | 268 |
| Treatment-related serious adverse events | 102 | 136 |
| TRAE leading to discontinuation of study drug | 51 | 54 |
| Treatment-related fatal adverse events | 5 | 10 |
Collected over From the first dose of any study drug up to 30 days after the last dose of any study drug as of the data cut-off date of 15 July 2016; median duration of treatment was 52 weeks in both treatment groups.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bortezomib, Melphalan, Prednisone | — | 198/470 (42.1%) | 437/470 (93%) |
| Carfilzomib, Melphalan, Prednisone | — | 235/474 (49.6%) | 437/474 (92.2%) |
| Event | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone |
|---|---|---|
| PneumoniaInfections and infestations | 31/470 | 46/474 |
| Cardiac failureCardiac disorders | 7/470 | 21/474 |
| Acute kidney injuryRenal and urinary disorders | 10/470 | 19/474 |
| PyrexiaGeneral disorders | 9/470 | 16/474 |
| Renal failureRenal and urinary disorders | 3/470 | 14/474 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/470 | 5/474 |
| AnaemiaBlood and lymphatic system disorders | 6/470 | 11/474 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/470 | 9/474 |
| Cardiac failure congestiveCardiac disorders | 0/470 | 8/474 |
| BronchitisInfections and infestations | 3/470 | 8/474 |
| Event | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 143/470 | 168/474 |
| PyrexiaGeneral disorders | 80/470 | 168/474 |
| NauseaGastrointestinal disorders | 132/470 | 167/474 |
| Neuropathy peripheralNervous system disorders | 154/470 | 29/474 |
| DiarrhoeaGastrointestinal disorders | 132/470 | 95/474 |
| NeutropeniaBlood and lymphatic system disorders | 121/470 | 121/474 |
| VomitingGastrointestinal disorders | 88/470 | 116/474 |
| ConstipationGastrointestinal disorders | 114/470 | 65/474 |
| HypertensionVascular disorders | 32/470 | 102/474 |
| ThrombocytopeniaBlood and lymphatic system disorders | 91/470 | 84/474 |
| Age, Continuous(years) | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone | Total |
|---|---|---|---|
| Mean | 71.5 ± 6.5 | 72.0 ± 5.7 | 71.7 ± 6.1 |
| Sex: Female, Male(Participants) | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone | Total |
|---|---|---|---|
| Female | 238 | 235 | 473 |
| Male | 239 | 243 | 482 |
| Ethnicity (NIH/OMB)(Participants) | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone | Total |
|---|---|---|---|
| Hispanic or Latino | 15 | 18 | 33 |
| Not Hispanic or Latino | 443 | 427 | 870 |
| Unknown or Not Reported | 19 | 33 | 52 |
| Race/Ethnicity, Customized(participants) | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 121 | 123 | 244 |
| Black or African American | 0 | 3 | 3 |
| White | 339 | 329 | 668 |
| Other | 3 | 1 | 4 |
| Multiple | 0 | 2 | 2 |
| Not Reported | 12 | 19 | 31 |
| Stratification Factor: International Staging System (ISS) Stage(participants) | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone | Total |
|---|---|---|---|
| Stage I | 99 | 95 | 194 |
| Stage II or III | 378 | 383 | 761 |
| Stratification Factor: Route of Bortezomib Administration(participants) | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone | Total |
|---|---|---|---|
| Intravenous | 123 | 123 | 246 |
| Subcutaneous | 354 | 355 | 709 |
| Stratification Factor: Region of Enrollment(participants) | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone | Total |
|---|---|---|---|
| Asia Pacific | 141 | 140 | 281 |
| North America | 12 | 8 | 20 |
| Europe | 317 | 320 | 637 |
| Other | 7 | 10 | 17 |
| Stratification Factor: Age(participants) | Bortezomib, Melphalan, Prednisone | Carfilzomib, Melphalan, Prednisone | Total |
|---|---|---|---|
| < 75 years | 329 | 327 | 656 |
| ≥ 75 years | 148 | 151 | 299 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 213 sites across 30 countries. Choose a country and city above to see the rest.
Ran from Jul 2013 to primary completion in Jul 2016, 36 months.
Results were first posted in Aug 2017, 1 year after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 36 months is below that.
Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carfilzomib